Literature DB >> 1990154

Pathologic mechanisms of drug-induced lung disorders.

G G Pietra1.   

Abstract

The pathology of drug-induced lung disease is approached on the basis of patterns of tissue reaction in this review. The entities described include various pathologic lesions, from diffuse alveolar damage to interstitial pneumonias and angiopathies. Because the histopathologic manifestations of drug injury are variable and nonspecific, pathogenetic mechanisms are emphasized. Drugs may cause injury by direct toxicity or by triggering immunologic responses, but often this neat distinction is blurred by the combined effects of preexisting lung injury and the concurrent administration of several drugs. Thus the identification of drug-induced lung disease requires thorough knowledge of the clinical history and rigorous analysis of histopathologic features.

Entities:  

Mesh:

Year:  1991        PMID: 1990154     DOI: 10.1097/00005382-199101000-00003

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  9 in total

1.  Drug induced interstitial lung disease.

Authors:  Martin Schwaiblmair; Werner Behr; Thomas Haeckel; Bruno Märkl; Wolfgang Foerg; Thomas Berghaus
Journal:  Open Respir Med J       Date:  2012-07-27

Review 2.  Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches.

Authors:  Osamu Matsuno
Journal:  Respir Res       Date:  2012-05-31

Review 3.  New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know.

Authors:  Frederico F Souza; Andrew Smith; Cyrillo Araujo; Jyothi Jagannathan; Ciaran Johnston; Kevin O'Regan; Atul Shinagare; Nikhil Ramaiya
Journal:  Cancer Imaging       Date:  2014-07-23       Impact factor: 3.909

4.  Acute eosinophilic pneumonia caused by camostat mesilate: The first case report.

Authors:  Shinichiro Ota; Yu Hara; Soichiro Kanoh; Masahiro Shinoda; Shuichi Kawano; Yuji Fujikura; Akihiko Kawana; Masaharu Shinkai
Journal:  Respir Med Case Rep       Date:  2016-06-16

5.  [Pulmonary complications in chemotherapy].

Authors:  A Becker; T Frauenfelder
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

6.  Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies.

Authors:  Kinnosuke Matsumoto; Takayuki Shiroyama; Tomoki Kuge; Kotaro Miyake; Yuji Yamamoto; Midori Yoneda; Makoto Yamamoto; Yujiro Naito; Yasuhiko Suga; Kiyoharu Fukushima; Shohei Koyama; Kota Iwahori; Haruhiko Hirata; Izumi Nagatomo; Yoshito Takeda; Atsushi Kumanogoh
Journal:  Transl Lung Cancer Res       Date:  2022-09

7.  Reversible lansoprazole-induced interstitial lung disease showing improvement after drug cessation.

Authors:  Kyu-won Hwang; Ok Hee Woo; Hwan Seok Yong; Bong Kyung Shin; Jae Jeong Shim; Eun-Young Kang
Journal:  Korean J Radiol       Date:  2008 Mar-Apr       Impact factor: 3.500

8.  Ground-glass opacity in lung metastasis from breast cancer: a case report.

Authors:  Sae Byol Kim; Soohyeon Lee; Myoung Ju Koh; In Seon Lee; Chan Soo Moon; Sung Mo Jung; Young Ae Kang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-01-31

9.  Tissue Adequacy and Safety of Percutaneous Transthoracic Needle Biopsy for Molecular Analysis in Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.

Authors:  Bo Da Nam; Soon Ho Yoon; Hyunsook Hong; Jung Hwa Hwang; Jin Mo Goo; Suyeon Park
Journal:  Korean J Radiol       Date:  2021-08-31       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.